Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Trial Profile

Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Coronary artery disease; Stent thrombosis
  • Focus Therapeutic Use
  • Acronyms IDEAL-PCI
  • Most Recent Events

    • 01 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top